Table 1. Randomized trials comparing platinum-based re-challenge versus single-agent chemotherapy in relapsed SCLC: main characteristics of patients.
| Characteristics | Inoue et al. (10) | Goto et al. (11) | |||
|---|---|---|---|---|---|
| Re-challenge | Amrubicin | Re-challenge | Topotecan | ||
| Phase of RCT | II | II | III | III | |
| No. pts | 30 | 27 | 90 | 90 | |
| Gender (male/female) (n) | 27/3 | 26/1 | 77/13 | 78/12 | |
| Median age (years) | 67 | 64 | 64 | 64 | |
| ECOG PS 0/1/2 (n) | 17/11/2 | 15/10/2 | 52/36/2 | 40/47/3 | |
| Initial stage LD/ED (n) | 18/12 | 15/12 | 20/70 | 25/65 | |
| First-line chemotherapy (n) | |||||
| Platinum-etoposide | 21 | 20 | 50 | 49 | |
| Platinum-irinotecan | 8 | 7 | 32 | 31 | |
| Platinum-amrubicin | 0 | 0 | 17 | 15 | |
| Relapse after 6 months (n) | – | – | NR | NR | |
| Yes | 18 | 16 | |||
| No | 12 | 11 | |||
| Time from first-line chemotherapy to relapse (days) | NR | NR | 181 | 148 | |
| Third-line chemotherapy (n) | 24 | 17 | 74 | 76 | |
SCLC, small-cell lung cancer; RCT, randomized clinical trial; No. pts, number of patients; n, number; ECOG PS, Eastern Cooperative Oncology Group performance status; LD, limited disease; ED, extensive disease; NR, not reported.